SuperworthAvalo Therapeutics market cap AVTX
Share price times shares outstanding: what the whole company sells for, since 2015.
- Today, Oct 23, 2026
- $371.7M
- Highest close in our data
- $1.1B
- Aug 2026
Avalo Therapeutics is worth $371.7M at the close on Oct 23, 2026, at $6.93 a share.
That is up 61% over the last year and up 65% over five years.
Its highest close in our data was $1.1B in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $371.7M | $243.4M | $1.1B | +12% |
| 2025 | $333.1M | $40.6M | $344.5M | +285% |
| 2024 | $86.6M | $3.4M | $138.3M | +1087% |
| 2023 | $7.3M | $1.8M | $58.3M | −85% |
| 2022 | $47.4M | $28.2M | $116.8M | −75% |
| 2021 | $190.9M | $187.3M | $350.4M | −3% |
| 2020 | $197.8M | $125.6M | $221.9M | −13% |
| 2019 | $226.3M | $125.7M | $252.2M | +77% |
| 2018 | $128.1M | $71.4M | $163.5M | +54% |
| 2017 | $83.4M | $4.7M | $83.4M | +923% |
| 2016 | $8.2M | $8.2M | $47.5M | −72% |
| 2015 | $28.9M | $26.9M | $38M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Avalo Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| AVTXAvalo Therapeutics | $371.7M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| NATRNatures Sunshine Products | $213.8M |
| COLLCollegium Pharmaceutical | $747.5M |
| ABUSArbutus Biopharma | $831M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.2B |
| Peer median | $597.2M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Avalo Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.